OrbiMed Advisors Acquires Additional Shares of RAPT Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RAPT?
Source: Fool
- Share Acquisition: On February 17, 2026, OrbiMed Advisors purchased an additional 556,273 shares of RAPT Therapeutics, with an estimated transaction value of $17.28 million based on the average closing price for Q4 2025, indicating strong confidence in the company's growth prospects.
- Holding Overview: Following this acquisition, OrbiMed's total holdings in RAPT reached 1,642,891 shares valued at $55.64 million, representing 1.1% of its 13F reportable AUM, highlighting its strategic positioning in the biotech sector.
- Market Reaction: RAPT announced on February 2, 2026, that it would be acquired by GSK for $58 per share, approximately 75% above its stock price of $33.15 on December 31, 2025, reflecting the high valuation large pharmaceutical companies place on promising immunology assets.
- Investment Outlook: RAPT focuses on developing oral small-molecule therapies for oncology and inflammatory diseases, with its anti-IgE antibody candidate ozureprubart aimed at preventing severe allergic reactions, addressing a significant health challenge faced by over 17 million people in the U.S., showcasing its market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RAPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RAPT
Wall Street analysts forecast RAPT stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 58.020
Low
56.00
Averages
67.78
High
95.00
Current: 58.020
Low
56.00
Averages
67.78
High
95.00
About RAPT
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OrbiMed Advisors Acquires Additional Shares of RAPT Therapeutics
- Share Acquisition: On February 17, 2026, OrbiMed Advisors purchased an additional 556,273 shares of RAPT Therapeutics, with an estimated transaction value of $17.28 million based on the average closing price for Q4 2025, indicating strong confidence in the company's growth prospects.
- Holding Overview: Following this acquisition, OrbiMed's total holdings in RAPT reached 1,642,891 shares valued at $55.64 million, representing 1.1% of its 13F reportable AUM, highlighting its strategic positioning in the biotech sector.
- Market Reaction: RAPT announced on February 2, 2026, that it would be acquired by GSK for $58 per share, approximately 75% above its stock price of $33.15 on December 31, 2025, reflecting the high valuation large pharmaceutical companies place on promising immunology assets.
- Investment Outlook: RAPT focuses on developing oral small-molecule therapies for oncology and inflammatory diseases, with its anti-IgE antibody candidate ozureprubart aimed at preventing severe allergic reactions, addressing a significant health challenge faced by over 17 million people in the U.S., showcasing its market potential.
See More
GSK Completes Acquisition of RAPT Therapeutics
- Acquisition Completed: GSK announced on Tuesday that it has successfully completed the acquisition of clinical-stage RAPT Therapeutics, which will enhance GSK's research capabilities in biopharmaceuticals and further expand its innovative drug portfolio.
- Strategic Importance: This acquisition allows GSK to gain access to RAPT's unique therapeutic platform, accelerating product development in immuno-oncology and other key areas, thereby enhancing its competitive position in the market.
- Financial Impact: While specific financial terms of the transaction have not been disclosed, it is expected to positively influence GSK's long-term growth prospects, particularly in the context of the rapidly growing biopharmaceutical market.
- Market Reaction: The market has reacted positively to GSK's acquisition, viewing it as a strategic move that will help the company secure a more advantageous position in future drug development, further solidifying its leadership in the industry.
See More
Great Point Partners Acquires Stake in RAPT Therapeutics
- New Position Disclosure: Great Point Partners disclosed a new position in RAPT Therapeutics, acquiring 581,187 shares in Q4 2026, reflecting strong confidence in the company with a stake valued at $19.68 million, accounting for 6.38% of its assets under management.
- Price Surge: As of February 17, 2026, RAPT Therapeutics' shares were priced at $57.84, skyrocketing 502.5% over the past year, significantly outperforming the S&P 500's 13% gain, indicating high market recognition of its potential therapies.
- Financial Overview: Despite a net loss of $105.64 million over the past year, RAPT holds $157.3 million in cash and marketable securities, demonstrating ongoing investment in R&D and financial stability.
- Strategic Acquisition Impact: GSK's acquisition of RAPT for $58 per share, totaling approximately $2.2 billion, highlights strong market interest in biotech, providing investors with potential high-return opportunities.
See More
GSK Acquires 35Pharma for $950 Million
- Acquisition Deal: GSK plc has agreed to acquire Canada-based clinical-stage biopharmaceutical company 35Pharma for $950 million, aiming to enhance its competitive edge in novel protein therapeutics, particularly in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure (PH-HFpEF).
- Clinical Advancement: The acquisition includes HS235, an investigational drug that has completed phase 1 trials in healthy volunteers, with studies set to commence imminently for PAH, indicating significant market potential as the global pulmonary hypertension therapy market is projected to reach $18 billion by 2032.
- Market Outlook: HS235 targets the activin receptor signaling pathway, expected to capture 50% of the pulmonary hypertension treatment market, and its design enhances selectivity, reducing binding to ligands associated with adverse events, showcasing its differentiated clinical application.
- Licensing Agreement: GSK has also entered into a deal with Frontier Biotechnologies, which will receive $40 million upfront and up to $963 million in milestone payments, responsible for advancing two investigational assets, while GSK will handle subsequent global clinical development and commercialization activities.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, raising concerns about potential violations of shareholder rights and encouraging shareholders to understand their options.
- Merger Transaction Review: The merger between Contango ORE, Inc. and Dolly Varden Silver Corporation will result in Contango shareholders owning approximately 50% of the combined entity, prompting Halper Sadeh LLC to assess whether this transaction serves the best interests of shareholders.
- Shareholder Equity Protection: Tamboran Resources Corporation's merger with Falcon Oil & Gas Ltd. will allow Tamboran shareholders to hold 73.2% of the combined company, with Halper Sadeh LLC urging shareholders to be aware of potential equity losses.
- Legal Support Services: Amicus Therapeutics, Inc. is being sold to BioMarin Pharmaceutical Inc. for $14.50 per share, and Halper Sadeh LLC offers no-cost legal consultations to assist shareholders in protecting their rights.
See More
Monteverde Law Firm Investigates RAPT and Others for Shareholder Recovery
- Shareholder Recovery Investigation: Monteverde & Associates is investigating RAPT Therapeutics, Inc.'s sale to GSK plc, with RAPT shareholders expected to receive $58.00 per share in cash, which could significantly enhance shareholder returns and bolster investor confidence.
- Amicus Transaction Update: In the proposed sale of Amicus Therapeutics, Inc. to BioMarin Pharmaceutical Inc., Amicus shareholders are anticipated to receive $14.50 per share in cash, with a shareholder vote scheduled for March 3, 2026, potentially impacting the company's future market performance.
- Merger Voting Arrangement: Tamboran Resources Corporation's merger with Falcon Oil & Gas Ltd. will result in Tamboran shareholders owning 73.2% of the combined entity, with a shareholder vote set for March 4, 2026, indicating the company's strategic positioning in industry consolidation.
- Contango Merger Details: The merger between Contango Ore, Inc. and Dolly Varden Silver Corporation will allow Contango shareholders to own 50% of the combined company, with a shareholder vote scheduled for March 17, 2026, which may present new growth opportunities for shareholders.
See More
OrbiMed Advisors Acquires Additional Shares of RAPT Therapeutics
- Share Acquisition: On February 17, 2026, OrbiMed Advisors purchased an additional 556,273 shares of RAPT Therapeutics, with an estimated transaction value of $17.28 million based on the average closing price for Q4 2025, indicating strong confidence in the company's growth prospects.
- Holding Overview: Following this acquisition, OrbiMed's total holdings in RAPT reached 1,642,891 shares valued at $55.64 million, representing 1.1% of its 13F reportable AUM, highlighting its strategic positioning in the biotech sector.
- Market Reaction: RAPT announced on February 2, 2026, that it would be acquired by GSK for $58 per share, approximately 75% above its stock price of $33.15 on December 31, 2025, reflecting the high valuation large pharmaceutical companies place on promising immunology assets.
- Investment Outlook: RAPT focuses on developing oral small-molecule therapies for oncology and inflammatory diseases, with its anti-IgE antibody candidate ozureprubart aimed at preventing severe allergic reactions, addressing a significant health challenge faced by over 17 million people in the U.S., showcasing its market potential.
See More
GSK Completes Acquisition of RAPT Therapeutics
- Acquisition Completed: GSK announced on Tuesday that it has successfully completed the acquisition of clinical-stage RAPT Therapeutics, which will enhance GSK's research capabilities in biopharmaceuticals and further expand its innovative drug portfolio.
- Strategic Importance: This acquisition allows GSK to gain access to RAPT's unique therapeutic platform, accelerating product development in immuno-oncology and other key areas, thereby enhancing its competitive position in the market.
- Financial Impact: While specific financial terms of the transaction have not been disclosed, it is expected to positively influence GSK's long-term growth prospects, particularly in the context of the rapidly growing biopharmaceutical market.
- Market Reaction: The market has reacted positively to GSK's acquisition, viewing it as a strategic move that will help the company secure a more advantageous position in future drug development, further solidifying its leadership in the industry.
See More
Great Point Partners Acquires Stake in RAPT Therapeutics
- New Position Disclosure: Great Point Partners disclosed a new position in RAPT Therapeutics, acquiring 581,187 shares in Q4 2026, reflecting strong confidence in the company with a stake valued at $19.68 million, accounting for 6.38% of its assets under management.
- Price Surge: As of February 17, 2026, RAPT Therapeutics' shares were priced at $57.84, skyrocketing 502.5% over the past year, significantly outperforming the S&P 500's 13% gain, indicating high market recognition of its potential therapies.
- Financial Overview: Despite a net loss of $105.64 million over the past year, RAPT holds $157.3 million in cash and marketable securities, demonstrating ongoing investment in R&D and financial stability.
- Strategic Acquisition Impact: GSK's acquisition of RAPT for $58 per share, totaling approximately $2.2 billion, highlights strong market interest in biotech, providing investors with potential high-return opportunities.
See More
GSK Acquires 35Pharma for $950 Million
- Acquisition Deal: GSK plc has agreed to acquire Canada-based clinical-stage biopharmaceutical company 35Pharma for $950 million, aiming to enhance its competitive edge in novel protein therapeutics, particularly in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure (PH-HFpEF).
- Clinical Advancement: The acquisition includes HS235, an investigational drug that has completed phase 1 trials in healthy volunteers, with studies set to commence imminently for PAH, indicating significant market potential as the global pulmonary hypertension therapy market is projected to reach $18 billion by 2032.
- Market Outlook: HS235 targets the activin receptor signaling pathway, expected to capture 50% of the pulmonary hypertension treatment market, and its design enhances selectivity, reducing binding to ligands associated with adverse events, showcasing its differentiated clinical application.
- Licensing Agreement: GSK has also entered into a deal with Frontier Biotechnologies, which will receive $40 million upfront and up to $963 million in milestone payments, responsible for advancing two investigational assets, while GSK will handle subsequent global clinical development and commercialization activities.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, raising concerns about potential violations of shareholder rights and encouraging shareholders to understand their options.
- Merger Transaction Review: The merger between Contango ORE, Inc. and Dolly Varden Silver Corporation will result in Contango shareholders owning approximately 50% of the combined entity, prompting Halper Sadeh LLC to assess whether this transaction serves the best interests of shareholders.
- Shareholder Equity Protection: Tamboran Resources Corporation's merger with Falcon Oil & Gas Ltd. will allow Tamboran shareholders to hold 73.2% of the combined company, with Halper Sadeh LLC urging shareholders to be aware of potential equity losses.
- Legal Support Services: Amicus Therapeutics, Inc. is being sold to BioMarin Pharmaceutical Inc. for $14.50 per share, and Halper Sadeh LLC offers no-cost legal consultations to assist shareholders in protecting their rights.
See More
Monteverde Law Firm Investigates RAPT and Others for Shareholder Recovery
- Shareholder Recovery Investigation: Monteverde & Associates is investigating RAPT Therapeutics, Inc.'s sale to GSK plc, with RAPT shareholders expected to receive $58.00 per share in cash, which could significantly enhance shareholder returns and bolster investor confidence.
- Amicus Transaction Update: In the proposed sale of Amicus Therapeutics, Inc. to BioMarin Pharmaceutical Inc., Amicus shareholders are anticipated to receive $14.50 per share in cash, with a shareholder vote scheduled for March 3, 2026, potentially impacting the company's future market performance.
- Merger Voting Arrangement: Tamboran Resources Corporation's merger with Falcon Oil & Gas Ltd. will result in Tamboran shareholders owning 73.2% of the combined entity, with a shareholder vote set for March 4, 2026, indicating the company's strategic positioning in industry consolidation.
- Contango Merger Details: The merger between Contango Ore, Inc. and Dolly Varden Silver Corporation will allow Contango shareholders to own 50% of the combined company, with a shareholder vote scheduled for March 17, 2026, which may present new growth opportunities for shareholders.
See More
